title: Prophylactic use of omeprazole associated with a reduced risk of peptic ulcer disease among maintenance hemodialysis patients.
abstract: BACKGROUND
  Patients undergoing maintenance hemodialysis (MHD) have a high prevalence of peptic ulcer disease (PUD). Omeprazole is a proton pump inhibitor with proven efficacy in the prevention and treatment of PUD. However, there is little data on the prophylactic use of omeprazole in reducing the risk of PUD among MHD patients.
  
  
  METHODS
  This prospective study included 93 patients undergoing MHD at Zen-Ho Dialysis Center between July 2008 and December 2009. Fifty-three patients were assigned to receive 20 mg of omeprazole daily for 18 months and 40 patients served as control. The Kaplan-Meier method was applied to calculate the cumulative incidence of PUD.
  
  
  RESULTS
  The per-protocol population comprised 85 patients (omeprazole group, 49; control group, 36). Both groups had similar baseline characteristics. The need for endoscopy was found to be significantly less (10.2 vs. 44.4%, p = 0.001) in the omeprazole group than in the control group. Dialysis patients in the omeprazole group required fewer blood transfusions and erythropoietin doses than did the control group patients. Kaplan-Meier analysis revealed a higher cumulative ulcer rate in the control group (log-rank test, p = 0.04). However, omeprazole did not reduce the risk of PUD in MHD patients on regular aspirin or warfarin.
  
  
  CONCLUSIONS
  We conclude that prophylactic use of omeprazole might be effective to lower the incidence of PUD among MHD patients without regular aspirin or warfarin use. Further large-scale controlled trials should be carried out to confirm our findings.
authors.affiliation: Kidney Institute and Division of Nephrology, Department of Internal Medicine, China Medical University Hospital, Taichung, Taiwan.
authors.forename: Chih-Chia
authors.initials: CC
authors.lastname: Liang
authors.forename: I-Kuan
authors.initials: IK
authors.lastname: Wang
authors.forename: Hsin-Hung
authors.initials: HH
authors.lastname: Lin
authors.forename: Hung-Chieh
authors.initials: HC
authors.lastname: Yeh
authors.forename: Jiung-Hsiun
authors.initials: JH
authors.lastname: Liu
authors.forename: Huey-Liang
authors.initials: HL
authors.lastname: Kuo
authors.forename: Wei-Min
authors.initials: WM
authors.lastname: Hsu
authors.forename: Chiu-Ching
authors.initials: CC
authors.lastname: Huang
authors.forename: Chiz-Tzung
authors.initials: CT
authors.lastname: Chang
mesh_terms: D000368:Aged; D000897:Anti-Ulcer Agents / Q000191:economics / Q000627:therapeutic use*; D003362:Cost-Benefit Analysis; D005260:Female; D006801:Humans; D007676:Kidney Failure, Chronic / Q000150:complications* / Q000628:therapy; D008297:Male; D008875:Middle Aged; D009853:Omeprazole / Q000191:economics / Q000627:therapeutic use*; D010437:Peptic Ulcer / Q000150:complications / Q000517:prevention & control*; D011446:Prospective Studies; D006435:Renal Dialysis
chemical_list: D000897:Anti-Ulcer Agents; D009853:Omeprazole